Circulating “LncPPARδ” From Monocytes as a Novel Biomarker for Coronary Artery Diseases

Cai, Yuchen; Yang, Yujia; Chen, Xiongwen; He, Duofeng; Zhang, Xiaoqun; Wen, Xiangming; Hu, Ji; Fu, Chunjiang; Qiu, Dongfeng; José, Pedro A.; Zeng, Chunyu; Zhou, Lin

doi:10.1097/md.0000000000002360

Cited by 36 publications

(23 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…107 The same group suggested LncPPARδ, which was elevated in circulating peripheral blood monocytes, as an additional CAD biomarker when combined with other risk factors. 109…”

Section: Coronary Artery Diseasementioning

confidence: 99%

Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury

Viereck

Thum

2017

Circulation Research

328

266

View full text Add to dashboard Cite

The discovery of thousands of noncoding RNAs (ncRNAs) has expanded our view on mammalian genomes and transcriptomes, as well as their organization and regulation. Accumulating evidence on aberrantly regulated ncRNAs, including short microRNAs, long ncRNAs and circular RNAs, across various heart diseases indicates that ncRNAs are critical contributors to cardiovascular pathophysiology. In addition, ncRNAs are released into the circulation where they are present in concentration levels that differ between healthy subjects and diseased patients. Although little is known about the origin and function of such circulating ncRNAs, these molecules are increasingly recognized as noninvasive and readily accessible biomarker for risk stratification, diagnosis and prognosis of cardiac injury, and multiple forms of cardiovascular disease. In this review, we summarize recent findings on biological characteristics of circulating ncRNAs and highlight their value as potential biomarker in selected pathologies of cardiovascular disease.

show abstract

“…107 The same group suggested LncPPARδ, which was elevated in circulating peripheral blood monocytes, as an additional CAD biomarker when combined with other risk factors. 109…”

Section: Coronary Artery Diseasementioning

confidence: 99%

Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury

Viereck

Thum

2017

Circulation Research

328

266

View full text Add to dashboard Cite

show abstract

“…8 With the progression of the disease, the content of PTX-3 secreted by endothelial cells (ECs), smooth muscle cells, monocytes, macrophages, and fibroblasts is increased in response to inflammatory state. 12 In spite of these modulations, many attempts have been focused on the application of natural compound and alternative medicine. 10,11 Up to the present, reduction of low-density lipoprotein, application of anticoagulant drugs, percutaneous coronary intervention, and coronary artery bypass surgery have been considered as routine therapies for atherosclerosis.…”

Section: Introductionmentioning

confidence: 99%

“…10,11 Up to the present, reduction of low-density lipoprotein, application of anticoagulant drugs, percutaneous coronary intervention, and coronary artery bypass surgery have been considered as routine therapies for atherosclerosis. 12 In spite of these modulations, many attempts have been focused on the application of natural compound and alternative medicine. 13 For instance, scientific literature highlighted the therapeutic effects of docosahexaenoic acid (DHA; all-cis-docosa-4,7,10,13,16,19-hexa-enoic acid) on different pathologies ( Figure 1A).…”

Section: Introductionmentioning

confidence: 99%

Docosahexaenoic acid reversed atherosclerotic changes in human endothelial cells induced by palmitic acid in vitro

Karbasforush

Nourazarian

Darabi

et al. 2018

Cell Biochemistry & Function

View full text Add to dashboard Cite

The current experiment showed that docosahexaenoic acid could reverse atherosclerotic changes in human endothelial cells induced by palmitic acid. The increased levels of interleukin-6 and prostaglandin E in atherosclerotic cells were returned to near-to-normal status. Gene expression analysis showed a reduced activity of genes participating in atherosclerotic endothelial cells treated by docosahexaenoic acid. The expression of genes related to cell clotting activity was also similar to that of normal cells.

show abstract

“…The lncPPARδ has been indicated to be a good biomarker for CAD [ 116 ]. LncPPARδ regulates the expression of neighboring protein-coding gene PPARδ which in turn acts on its targets ADRP and ANGPTL4.…”

Section: Long Non-coding Rnas In Complexes Diseasesmentioning

confidence: 99%

Long Non-Coding RNAs in Multifactorial Diseases: Another Layer of Complexity

Cipolla

Oliveira

Salviano-Silva

et al. 2018

ncRNA

View full text Add to dashboard Cite

Multifactorial diseases such as cancer, cardiovascular conditions and neurological, immunological and metabolic disorders are a group of diseases caused by the combination of genetic and environmental factors. High-throughput RNA sequencing (RNA-seq) technologies have revealed that less than 2% of the genome corresponds to protein-coding genes, although most of the human genome is transcribed. The other transcripts include a large variety of non-coding RNAs (ncRNAs), and the continuous generation of RNA-seq data shows that ncRNAs are strongly deregulated and may be important players in pathological processes. A specific class of ncRNAs, the long non-coding RNAs (lncRNAs), has been intensively studied in human diseases. For clinical purposes, lncRNAs may have advantages mainly because of their specificity and differential expression patterns, as well as their ideal qualities for diagnosis and therapeutics. Multifactorial diseases are the major cause of death worldwide and many aspects of their development are not fully understood. Recent data about lncRNAs has improved our knowledge and helped risk assessment and prognosis of these pathologies. This review summarizes the involvement of some lncRNAs in the most common multifactorial diseases, with a focus on those with published functional data.

show abstract

Circulating “LncPPARδ” From Monocytes as a Novel Biomarker for Coronary Artery Diseases

Abstract: Supplemental Digital Content is available in the text

Cited by 36 publications

References 48 publications

Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury

Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury

Docosahexaenoic acid reversed atherosclerotic changes in human endothelial cells induced by palmitic acid in vitro

Long Non-Coding RNAs in Multifactorial Diseases: Another Layer of Complexity

Contact Info

Product

Resources

About